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ABSTRACT 
 
The transcription factor, peroxisome proliferator activated-receptor = (PPAR=), 
regulates many processes critical for normal ovarian function.  The role of PPAR= in the 
ovary was investigated by determining its expression throughout the bovine estrous cycle, 
and luteal tissue was cultured with agonists and an antagonist of PPAR= to determine its 
impact on progesterone production.  Protein, but not mRNA for PPAR=, was lower in 
regressing compared to functional luteal tissue.  Treatment with a PPAR= agonist 
decreased progesterone secretion from late phase luteal tissue.  These findings indicate 
that PPAR= may play a role in luteal formation/function, and alter progesterone 
production during specific stages of the ovarian cycle.  To facilitate further study of how 
PPAR= impacts ovarian biology, transgenic mice were developed with the gene for 
PPAR= specifically disrupted in granulosa cells.  Knowing what genes are regulated by 
PPAR= in the ovary will aid in understanding the mechanisms behind the cyclic pattern 
of gene expression driving normal ovarian function.
1CHAPTER 1.  INTRODUCTION 
An important player involved in female fertility is the ovary.  Proper 
functioning of the ovary is necessary for reproduction.  Therefore, understanding 
what drives ovarian gene expression allowing it to function in a cyclic pattern will 
enhance efforts towards improving reproduction in animals and humans.  The studies 
described below investigated the effects of a family of transcription factors, the 
peroxisome proliferator-activated receptors (PPARs), on ovarian function. 
 The PPARs are a family of nuclear hormone receptors composed of three 
distinct isotypes: F, G, and = [1-3].  These transcription factors are ligand activated 
and regulate gene expression by binding to the promoter region of the target gene.  
The PPARs have been identified in an array of tissues such as the heart and kidney, 
and from a number of species, for example the rat, human, and bovine.  The PPARs 
regulate a spectrum of physiological processes, many of which are involved in 
ovarian function (i.e. steroidogenesis, angiogenesis, and tissue remodeling).  
Numerous ligands, such as prostaglandins, fatty acids, and leukotrienes, that activate 
the PPARs are found in the ovary and have well documented effects on ovarian 
biology.  Therefore, the PPARs may mediate the effect of these factors on ovarian 
function, and the presence of ligands for the PPARs in ovarian tissue indicate a 
potential regulatory role for the PPARs in ovarian gene expression. 
 Previous work from our laboratory has established that all three PPARs are 
present in the rat ovary [4].  However, only PPAR= is differentially expressed in 
ovarian tissue.  PPAR= is also the only PPAR isotype that is differentially expressed 
throughout the ovarian cycle [4-6].  In the bovine, the only PPAR that has thus far 
been identified in the ovary is PPAR= [7].  Agonists of PPAR= have been reported to 
stimulate production of progesterone from mid-cycle luteal tissue when cultured in 
2vitro [8]. The expression and function of PPAR= during the remainder of the ovarian 
cycle has not, to our knowledge, been investigated in cattle.   
 To examine the potential roles of the PPARs in the ovary, the following set of 
experiments were conducted using the heifer as a model.  The expression of mRNA 
and protein for PPAR= was characterized at different stages of the ovarian cycle.  To 
determine what role PPAR= plays in progesterone production, luteal tissue was 
cultured in the presence and absence of agonists and an antagonist of PPAR=.
Additionally, a transgenic mouse colony, utilizing the cre/loxP system of tissue 
specific gene ablation, was established to facilitate study of the roles PPAR= plays in 
the ovary. 
 
ORGANIZATION OF THESIS 
 This thesis, submitted by the author for the degree of Master of Science, is 
presented in five parts.  Immediately following this chapter is a review of literature 
pertinent to ovarian function and the peroxisome proliferator activated-receptors 
(PPARs).  The experiments conducted to investigate the role of the PPARs in ovarian 
function are divided into one chapter and an appendix.  Chapter 3 reports the findings 
of PPAR expression and function in the bovine ovary and is followed by a chapter 
containing general conclusions.  Appendix 1 discusses an additional study involving 
the establishment of a transgenic mouse colony to disrupt PPAR= expression 
specifically in ovarian tissue. 
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4CHAPTER 2.  LITERATURE REVIEW 
 
The Ovary 
Structure.  Successful reproduction in mammalian females is dependent upon 
the ovary for gamete and hormone production.  The ovary is composed of three 
regions: the cortex, medulla, and hilus (Figure 2-1).  The cortex, or outer most region, 
consists of stromal tissue embedded with follicles and the corpus luteum (CL).  The 
inner region of ovarian tissue, or medulla, is largely composed of interstitial tissue 
and primarily plays a supportive role to the cortex by aiding in steroid production.  
The third region, the hilus, consists of blood vessels, nervous tissue, and ligaments 
encased in connective tissue that attaches the ovary to the vascular and central 
nervous systems [1].  This review will focus on events occurring in the cortex, 
namely follicular development, ovulation, and CL formation and regression.  
Function.  Sexually mature females undergo a cyclic pattern of follicular 
development that results in release of a mature oocyte (commonly referred to as the 
egg), at the time of ovulation.  After ovulation, the remaining follicular tissue 
differentiates into a CL through the process of luteinization. In the absence of 
fertilization, the luteal tissue will regress (luteolysis), allowing for the beginning of 
the next ovarian cycle. 
The ovary is also responsible for producing hormones critical to reproductive 
biology.  Two of these hormones are estradiol and progesterone.  Estradiol, the most 
active estrogen, is secreted from the granulosa cells of ovarian follicles.  
Progesterone, synthesized and released from the CL, is necessary for the 
establishment and maintenance of pregnancy.  Estradiol and progesterone play 
important roles in regulating the ovarian cycle, in addition to other hormones 
produced by the ovary, hypothalamus, and anterior pituitary. 
 
5The Ovarian Cycle 
The ovarian cycle is divided into two phases: the follicular phase and the 
luteal phase.  The follicular phase involves the formation, growth, and maturation of 
follicles through a process termed folliculogenesis.  Upon follicular maturation, 
ovulation occurs and the mature gamete is released from the ovary for potential 
fertilization.  Following ovulation, the luteal phase begins as the ruptured follicular 
tissue begins to luteinize and differentiates into luteal tissue.  These cellular changes 
and tissue remodeling lead to a shift in cellular function from aiding in the 
development of a mature gamete, to providing an environment conducive to the 
establishment and maintenance of pregnancy should the oocyte be fertilized.  If 
fertilization does not occur, the luteal tissue regresses, allowing for a new follicle to 
mature, and the cycle starts over again. 
Follicular Phase.  An ovarian follicle is the fundamental unit involved in the 
production of mature female gametes.  The most immature form of the follicle is 
referred to as the primordial follicle and consists of an oocyte surrounded by a single 
layer of flattened epithelial cells (Figure 2-2).  The development of primordial 
follicles into primary follicles is characterized by growth of the oocyte and transition 
of the surrounding flattened epithelial cells to cuboidal granulosa cells.  The 
granulosa cells produce a basement membrane, termed the basal lamina.  Follicular 
growth through this stage of development occurs very slowly.  The primordial to 
primary follicular transition takes approximately 2 to 3 months and begins before 
birth in most mammalian species [2;3].  Maturation of a primary follicle into a 
secondary follicle takes significantly longer.  In the bovine, formation of a secondary 
follicle takes years [1].  Several changes must occur to the primary follicle before it 
can be defined as a secondary follicle [3].  Oocyte growth continues and a 
glycoprotein rich substance known as the zona pellucida is produced.  The width of 
the cellular layer surrounding the oocyte increases as the granulosa cells proliferate 
6and form a second, concentric ring around the oocyte.  A second type of follicular 
cell, the theca, accumulates on the exterior side of the basal lamina.  Theca cells are 
derived from ovarian stromal tissue, and are associated with the vascular tissue.  The 
basal lamina blocks vascularization of the granulosa cells, therefore, the blood vessels 
in the thecal layer provide nutrients that diffuse across the basal lamina into the 
avascular granulosa cell and oocyte compartment [4].   
Development beyond the secondary follicle stage occurs more rapidly than the 
previous stages.  The granulosa cells continue to proliferate as the tissue layer 
surrounding the growing oocyte thickens [2].  Upon reaching the next stage of 
follicular development, referred to as the tertiary stage, the granulosa cells begin to 
secrete fluid.  The fluid between individual granulosa cells coalesces and creates a 
cavity inside the follicle called an antrum.  The appearance of the antrum marks the 
transition of the tertiary follicle into an antral follicle.  Growth of the oocyte, antrum, 
thecal, and granulosa cell layers continues as the antral follicle further matures into a 
Graafian, or preovulatory follicle [5].   
During each ovarian cycle, a cohort of antral follicles begins to grow in a 
process named recruitment [6].  Follicles that have been recruited either undergo 
atresia or continue to grow into medium sized antral follicles.  A single follicle 
emerges earlier from the cohort, giving it a growth advantage over the other follicles.  
The morphologically larger follicle is termed the dominant follicle.  The dominant 
follicle is the follicle that is capable of developing into an ovulatory follicle in the 
proper hormonal environment, while the other smaller follicles (subordinate follicles) 
regress.  This larger follicle exerts ‘dominance’ over the smaller, subordinate follicles 
by producing hormones that change the endocrine environment to one that does not 
support further growth of the smaller follicles.  Therefore, the subordinate follicles 
will undergo atresia through apoptosis [2;3;6]. 
7Luteal phase.  Following ovulation, granulosa and theca cells differentiate 
into large and small luteal cells, respectively.  In the days following ovulation, the 
corpus luteum increases in size by increasing the cytoplasmic:nuclear ratio of large 
lutein cells.  This increase in cellular cytoplasm is accompanied by an increase in the 
cellular organelles associated with steroid production, such as mitochondria, smooth 
endoplasmic reticulum, and Golgi apparati [7].  Expression of mRNA for 
steroidogenic enzymes switches from what is necessary for estradiol production to 
that needed for progesterone production.  Progesterone is secreted by the CL and is 
required to establish and maintain pregnancy if the ovulated oocyte becomes 
fertilized [8;9].  Blood flow to the CL also increases shortly after ovulation [10].  The 
CL goes through a period of intensive angiogenesis until nearly every luteal cell is in 
contact with one or more capillaries [11].   
 If fertilization does not occur, the CL undergoes a process called luteolysis in 
which the CL regresses.  Luteolysis, or the demise of the corpus luteum, occurs in 
two stages [9].  First, functional demise occurs resulting in decreased capacity for 
progesterone production and secretion.  A decrease in progesterone coupled with 
other factors then leads to the structural demise of luteal tissue [12].  In most 
mammalian models of luteolysis, regression is dependent upon synthesis and release 
of prostaglandin F2F (PGF2F) from the uterus.  If no embryo is present, PGF2F is 
released from the uterus and induces luteolysis.  In the presence of an embryo, the 
release of PGF2F is inhibited to prevent luteal regression and maintain pregnancy.  
Secondly, structural demise is characterized by a decrease in luteal cell number and 
size.  Apoptosis is dramatically increased in the endothelial cells of capillaries in the 
corpus luteum resulting in the degradation of vascular tissue and accompanied by a 
decrease in blood flow.  As less blood reaches the luteal tissue, a reduction in oxygen 
and nutrient delivery to luteal cells facilitates corpus luteum regression [7; 9]. 
 
8Regulation of Ovarian Function 
Regulation of folliculogenesis is largely controlled by communication 
between the ovary, pituitary and hypothalamus - the hypothalamic-pituitary-gonadal-
axis.  Two critical hormones, released from the anterior pituitary in response to 
gonadotropin releasing hormone (GnRH) from the hypothalamus, are luteinizing 
hormone (LH) and follicle stimulating hormone (FSH).  These gonadotropic peptide 
hormones bind to the appropriate G protein-coupled receptor and affect follicular 
development and steroid production by modulating the cyclic AMP (cAMP) and/or 
the protein kinase A (PKA) second messenger systems.  Granulosa cells become 
responsive to FSH when the FSH receptor begins to be expressed in the secondary 
follicle.  LH receptors are expressed in theca cells, as well as in granulosa cells of 
antral follicles [1].  
Estradiol production is the result of cooperation between theca and granulosa 
cells [13].  Both granulosa and thecal cells contain the enzymes needed to convert 
cholesterol to progesterone.  However, the expression of enzymes necessary to 
complete estradiol synthesis are specific to each follicular cell type.  Conversion of 
progesterone into androgens is dependent upon the enzyme 17F-hydroxylase which is 
expressed in the theca.  Aromatase, the enzyme required for the final step in the 
conversion of androgens to estradiol, is expressed in the granulosa cell [13].  For 
estradiol synthesis to be complete, androgens produced in the theca must diffuse into 
the granulosa cell compartments for aromatization to estrogen.  The 
compartmentalization of enzymes necessary for estradiol production prevents 
estradiol production from primordial or primary follicles.   
 Throughout the follicular stage of the ovarian cycle, secretion of FSH and LH 
from the pituitary increases due to greater stimulation by estradiol as follicles grow 
[5].  Activated estrogen receptors in the anterior pituitary stimulate an increase in the 
release of gonadotropins.  FSH and LH in turn, stimulate granulosa and theca cell 
9steroid production.  This positive feed-forward mechanism causes greater estrogen 
production.  As a result, more estrogen is produced and released as the follicles 
mature.  When the dominant follicle reaches ovulatory size, the increased production 
of estradiol triggers a large pulse of LH and FSH to be released from the pituitary.  
This gonadotropin surge, often called the LH surge because it is released in a greater 
concentration relative to FSH, causes the follicle to rupture and release the oocyte.  
The remaining follicular tissue involutes and begins to undergo luteinization.  
Progesterone produced from the CL inhibits the surge release of gonadotropins from 
the pituitary, preventing ovulation from occurring.  As the CL regresses, progesterone 
production decreases and allows gonadotropin secretion to increase.  Follicular 
growth and maturation marks the beginning of the next ovarian cycle [14]. 
 
Peroxisome Proliferator-Activated Receptors 
The peroxisome proliferator-activated receptors (PPARs) are a subfamily of 
nuclear hormone receptors involved in the regulation of gene expression.  These 
transcription factors play an important role in the transmission of endocrine, 
metabolic, and environmental signals to the cell nucleus.  The are three isotypes: F,
G1, and =. All three isotypes are differentially expressed in a wide range of tissues, and 
have been detected in numerous species.  Members of the PPAR family regulate a 
large number of genes that are involved in a diverse array of physiological processes.  
 
Background 
In the 1980’s, scientists investigated a diverse group of chemicals that induced 
peroxisomal G-oxidation of fatty acids [15;16].  These compounds, termed 
 
1. PPARG is also known as PPARM or NUC1 
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peroxisome proliferators, are composed of fibrates, plasticizers, and other 
environmental agents.  Of particular interest were the fibrates, due to their frequent 
use as hypolipidemic drugs (i.e. clofibrate, nafenopin) [16].  In humans, 
administration of fibrates resulted in decreased levels of triglycerides and cholesterol 
[17].  In rodents however, prolonged administration (3 – 5 years) of these drugs 
resulted in hepatocarcinomas, an effect not observed in humans [18].  In 1990, 
Issemann and Green reported the isolation and cloning of a novel receptor from rats 
that bound peroxisome proliferators which they named the peroxisome proliferator-
activated receptor (PPAR).  Data collected from reporter construct assays provided 
evidence of receptor activation by an array of peroxisome proliferators including, the 
hypolipidaemic drugs nafenopin and clofibrate, as well as other exogenous ligands.  
Comparison of the PPAR amino acid sequence with other known sequences identified 
several members of the nuclear hormone receptor superfamily that shared significant 
homology [19].  Based on the structural and functional characterization, it was 
hypothesized that PPAR was a member of the nuclear hormone receptor superfamily 
of transcription factors. 
In the years following Issemann and Green’s discovery and sequencing of the 
first PPAR, numerous studies in other species corroborated and provided further 
information about its structure.  Several groups isolated and cloned proteins 
homologous to PPAR in the rat [20], Xenopus [21], and human [22;23].  While 
isolating clones in Xenopus laevis, low stringency hybridization revealed three 
different cDNA inserts that were highly homologous to the mouse PPAR sequence.  
Further analysis verified the presence of three unique genes, each encoding a distinct 
protein [21].  The identification of two additional PPAR isotypes revealed that the 
PPARs composed a sub-family of nuclear hormone receptors.  To distinguish each 
isotype, the initial PPAR discovered by Issemann and Green was identified as PPARF
and the newly cloned isotypes where named PPARG and PPAR=. Subsequent studies 
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determined that the PPARs heterodimerize with retinoid X receptors [25], and bind to 
a specific DNA response element termed the peroxisome proliferator activated-
receptor response element [24].  The PPARs were also found to be activated by 
numerous endogenous ligands such as fatty acids and prostaglandins [20;22;26;27]. 
Structure. Nuclear hormone receptors share a motif structure composed of 
several well conserved domains (Figure 2-3).  The A/B domain is the most variable 
domain in sequence and size among nuclear hormone receptors [28].  This functional 
domain is located nearest to the N-terminus, typically contains an activation function 
1 (AF-1) element, and is a site of receptor phosphorylation and alternative splicing 
[28;29].  The most conserved functional domain among nuclear hormone receptors is 
the C domain, which is also referred to as the DNA-binding domain [28].  This 
protein domain contains two zinc-fingers that interact with sequence specific DNA 
response elements of the target gene [30].  Structural domain D is the hinge region of 
nuclear hormone receptors.  This module allows rotation between the DNA binding 
and ligand binding domains [28].  The E/F domain is the site of ligand binding and is 
responsible for mediating the cellular signals that regulate gene expression.  The E/F 
module is also the location of receptor homo- or heterodimerization [28].  The ligand 
binding domain of the PPARs is much larger than that in other nuclear hormone 
receptors.  This increased size of the binding pocket allows for a diverse group of 
compounds, varying in size and shape, to act as ligands [31].   
 There are alternative promoters and splice sites within PPARG and PPAR=
that result in multiple isoforms [32].  Alternative splicing of PPARG produces four 
different mRNA transcripts that all produce the same functional protein [33].  
Similarly, four different splice variants of PPAR= have been isolated [34].  
Transcripts of PPAR=1, =3, and =4 all produce the same functional protein, PPAR=1.
The PPAR=2 mRNA splice variant yields the PPAR=2 protein, which differs from 
PPAR=1 by an additional 30 amino acids at the N-terminal region [35].  PPAR=2 is 
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expressed primarily in adipose tissue while PPAR=1 is expressed in a broad range of 
tissues [36].  In all species tested, aside from humans, a single, full length transcript 
of PPARF is present.  In addition to the full length PPARF mRNA in humans, a 
second splice variant exists that lacks the ligand binding domain and hinge region 
[37].   
Ligands. Activation of nuclear hormone receptors can be induced by a wide 
variety of compounds.  Hormones, endogenous metabolites, and synthetic and 
environmental molecules commonly act as ligands for nuclear hormone receptors 
(reviewed by [38]; [39]).  Common endogenous ligands such as eicosanoids 
(prostaglandins and leukotrienes) and fatty acids can bind to all members of the 
PPARs [32].  Both saturated and unsaturated fatty acids bind to all PPAR isotypes, 
although fatty acids are bound with greatest affinity by PPARF [40].  Eicosanoids 
also bind to each PPAR isotype, however each isotype binds to a specific 
prostaglandin derivative.  For example, prostacyclin (PGI2) binds specifically to 
PPARG [41].  Exogenous ligands consist of a number of environmental agents – 
herbicides, plasticizers, and various plant extracts.  Some PPAR ligands also exhibit 
species specificity.  An investigation by Krey et al. (1997) reported that for Xenopus, 
the fibrates, bezafibrate and ciprofibrate, activated PPARG and PPAR=, respectively.  
In mammals however, both bezafibrate and ciprofibrate activate PPARF and do not 
act as ligands for PPARG and PPAR= [42;43].  Exogenous ligands for PPAR= consist 
of compounds from the thiazolidnedione (TZD) class of drugs (i.e. rosiglitazone, 
ciglitazone) and nonsteroidal anti-inflammatory drugs (i.e. ibuprofen, indomethacin) 
[38].  Endogenous ligands include eicosinoids (i.e. prostaglandin J2 (PGJ2) and 
leukotrienes, polyunsaturated fatty acids (i.e. lysophosphatidic acid, linoleic acid), 
and low density lipoprotein [32;44].   
DNA Binding. Binding of the PPARs to target DNA requires 
heterodimerization with a retinoid X nuclear hormone receptor [25;45].  Similar to 
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the PPARs, the RXRs are a family of nuclear hormone receptors that are ligand 
dependent and require the binding of 9-cis-retinoic acid [25].  The heterodimerization 
of PPAR and RXR to form the PPAR activated complex (PPAR:RXR) can occur with 
or without binding of their respective ligands [46].  To regulate gene expression, the 
activated PPAR complex binds to the promoter region of the target gene at a sequence 
specific DNA element termed the peroxisome proliferator response element [19].  
The peroxisome proliferator response element is composed of duplicate hexamer 
consensus sequences (AGGTCA) separated by a single nucleotide [24;25].  The 
sequence contains a direct-repeat element (DR-1) that is highly conserved by most 
members of the nuclear hormone receptor family [28].  Binding of the PPAR:RXR 
complex to the peroxisome proliferator response element involves the binding of the 
PPAR to the upstream hexamer and RXR to the most 3’ repeat [47;48].   
 
Tissue Expression Patterns and Physiological Functions 
PPAR0. PPARF is involved in the regulation of fatty acid and lipid 
metabolism and atherosclerosis [36;49].  In the adult rodent, PPARF is highly 
expressed in metabolically active tissues such as the liver, stomach, kidney, and 
intestine [50].  PPARF is also expressed in the testis, ovary, uterus, heart, immune 
cells, and other tissues at lower levels [50].  In the human, expression of PPARF is 
greatest in the liver, heart, kidney, skeletal muscle, intestine, and pancreas, and also in 
the lung, placenta, and adipose tissue at a lower level [43]. 
 One pathway regulated by PPARF in a feed-forward mechanism is the 
peroxisomal G-oxidation of fatty acids.  A study by Göttlicher et al. (1992) 
established that long chain fatty acids activated chimeric reporter constructs 
containing the PPARF ligand binding domain.  Additional evidence from Tugwood et 
al. (1992), demonstrated that the promoter of the rat acyl CoA oxidase gene, the rate-
limiting enzyme of peroxisomal G-oxidation of long chain fatty acids, contained a 
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peroxisome proliferator response element.  Data from this study also demonstrated 
that PPARF bound to the peroxisome proliferator response element of acyl CoA 
oxidase and mediated the effects of the peroxisome proliferators [24].  PPARF also 
regulates other enzymes utilized in the peroxisomal G-oxidation pathway, such as 
enoyl-CoA hydratase/dehydrogenase and keto acyl-CoA thiolase [32].  The 
generation of PPARF knock-out mice [51] demonstrated that several mitochondrial 
enzymes from the liver (i.e. very long chain acyl CoA dehydrogenase and short 
chain-specific 3-ketoacyl-CoA thiolase) were expressed at lower levels in PPARF
null mice compared to wild-type mice [52].  Many of the mitochondrial genes 
regulated by PPARF are involved in the mitochondrial G-oxidation of fatty acids.  
Unlike the long chain fatty acids metabolized by G-oxidation in peroxisomes, 
mitochondrial G-oxidation utilizes shorter fatty acids.  PPARF also regulates the 
expression of carnitine palymitoyl transferase I, and medium-chain acyl-CoA 
dehydrogenase, all of which are enzymes critical in mitochondrial G-oxidation [32].  
These data provide evidence that PPARF regulates both peroxisomal and 
mitochrondial G-oxidation and strongly suggests that PPARF is critical to fatty acid 
homeostasis. 
 PPARF is also involved in mediating inflammatory responses.  Devchand et 
al. (1996) reported that PPARF interacts directly with leukotriene B4, a potent fatty 
acid derivative involved in local immune responses.  Data obtained from PPARF
knock-out mice demonstrated that in response to treatment with leukotriene B4, mice 
null for PPARF exhibited a prolonged inflammatory response compared to wild-type 
littermates [53].  PPARF null mice eventually recovered the ability to control 
inflammation, indicating that leukotriene B4 was metabolized, however at a slower 
rate likely via basal G-oxidation or an alternative pathway [53].  Evidence also 
suggests that PPARF works in concert with human macrophages to induce apoptosis.  
Chinetti et al. (1998) reported that agonists of PPARF induced cellular apoptosis via 
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interference with the anti-apoptotic factor NFB in cytokine-activated human 
macrophages [36]. 
 In the ovary, PPARF is ubiquitously expressed in follicular and luteal tissue 
[64].  Knock-out mice null for PPARF reproduce normally [53], however in mice 
with activated PPARF, the expression and activity of the enzyme aromatase is 
decreased [63].  To determine the role of PPARF in steroidogenesis and if it plays a 
role in reproduction, further study is needed.   
 PPAR1. PPARG is ubiquitously expressed in the rodent and human.  Of the 
three PPAR isotypes, PPARG is usually expressed at a greater relative level than 
PPARF and PPAR= in corresponding tissues [43;50].  Although expression is 
relatively steady between most tissues, PPARG is abundantly expressed during 
embryonic development [54].  During this time, expression of PPARG is particularly 
high in the brain, suggesting that PPARG may play a role in the cellular 
differentiation of the central nervous system [43;54].  The generation of PPARG
knock-out mice provided further evidence for a role of PPARG in development [37].  
Mice lacking PPARG had smaller brain diameters and exhibited altered patterns of 
myelination in the central nervous system as compared to wild-type mice [37].  
Additionally, PPARG null mice were, on average, smaller than normal.  Mice with 
ablated PPARG expression weighed significantly less and had shorter crown-rump 
lengths than wild-type litter mates [37].  
 The role of PPARG in fertility has also been investigated.  The prostaglandin, 
prostacyclin, is a ligand that binds selectively to PPARG [40;42;55].  In a recent study 
PPARG knock-out mice were used to investigate the role of PPARG in placental 
development [56].  Embryos of PPARG knock-out mice collected on embryonic day 
9.5 (E9.5) and E10.5 demonstrated a direct involvement of PPARG in promoting 
trophoblast cell differentiation [56].  PPARG further plays an important role in 
fertility by mediating the effects of prostacyclin during embryo implantation [57].   
16
PPAR2. Studies in the rodent have established that expression of PPAR=1
occurs in a large array of tissues including the heart, liver, kidney, and skeletal 
muscle.  Expression of PPAR=2 is present primarily in brown adipocytes, but has 
been isolated at low levels in other tissues [36].   
A primary function of PPAR= is as a regulator of adipocyte differentiation 
[26].  PPAR= was the first adipocyte-specific transcription factor to be cloned and 
identified.  It can activate the adipocyte fatty acid-binding protein (aP2) enhancer 
[26].  In addition, PPAR= has been described to target the expression of genes 
necessary for lipid accumulation, such as lipoprotein lipase, fatty acid transporter 
protein, acyl-CoA synthetase, and phosphoenolpyruvate carboxy kinase [36;58].  
Further validation of the role of PPAR= in adipogenesis was demonstrated by 
inducing ectopic expression of PPAR= in fibroblasts cells, which stimulated their 
differentiation into to pre-adipocytes [59]. 
The role of PPAR= in steroidogenesis has also been investigated.  Activation 
of PPAR= in human and eCG-primed rat granulosa cell cultures causes a decrease in 
the expression of aromatase, the rate limiting enzyme in estradiol production [62;63].  
However, a previous study using a different strain of rat found that cultured granulosa 
cells treated with agonists of PPAR= increased estradiol production [64].  PPAR= also 
regulates progesterone production in the bovine [65; 60], pig [66], rat [67], and sheep 
[68].  An inverse relationship between expression of mRNA for PPAR= and P450 
side chain cleavage, the rate limiting enzyme for progesterone synthesis has been 
observed [69, 67].  Although the exact function of PPAR= in steroidogenesis remains 
to be determined, evidence clearly suggests a role for PPAR=.
PPAR= has also been implicated in the regulation of angiogenesis and tissue 
remodeling.  Angiogenesis is a process critical for development of a mature and 
healthy CL, the most highly vascularized organ in the body.  Vascular endothelial 
growth factor (VEGF) is found in many tissues, including the follicle and corpus 
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luteum.  Agonists of PPAR= have been show to inhibit the activation of VEGF 
[70;71].   
An investigation by Cui et al., [73] suggests that PPAR= may play a direct 
role in the regulation of fertility.  Mice with tissue specific knock-down of PPAR= in 
mammary tissue, B and T cells, and granulosa cells produced, on average, litters with 
fewer numbers of pups when compared to wild-type liter-mates without reduced 
expression of PPAR=. Also, mice with diminished expression of PPAR=, on average, 
took more days to conceive than did their wild-type liter mates.  Thus far, data from 
the study by Cui et al. (2002) present the most convincing evidence that PPAR= plays 
a major role in female fertility.  
In conclusion, the PPARs are important regulators of several physiological 
processes necessary for ovarian function.  Understanding the functions and 
mechanisms involved in PPAR mediated regulation of the ovary is essential to 
overcoming reproductive problems. 
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Figure 2-1. Schematic diagram depicting the structure of the ovary. Figure adapted 
from Ojeda, 2004 [1]. 
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Figure 2-2.  Diagram of follicular growth and maturation.  Times refer to 
development in the human.  Diagram from Ojeda, 2004 [1]. 
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Figure 2-3.  Modular domain structure of the peroxisome proliferator activated-
receptors. AF-1: activating function 1 element; A/B domain; C domain or DNA 
binding domain; D domain or hinge region; E/F domain or ligand binding domain.  
Figure from Escriva et al., 2004.
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CHAPTER 3.  EXPRESSION OF PEROXISOME 
PROLIFERATOR ACTIVATED-RECEPTOR 2 (PPAR2) IN THE 
BOVINE OVARY AND ITS ROLE IN LUTEAL PROGESTERONE 
PRODUCTION 
A paper to be submitted to the Journal of Dairy Science 
Lacey J. Luense, Steven E. Hopkins, Carolyn M. Komar 
 
ABSTRACT 
Declining reproductive efficiency in dairy cattle is a major issue affecting the 
dairy industry.  The metabolic demands of lactation and compromised nutritional 
status of the female during lactation can negatively impact reproductive performance.  
The peroxisome proliferator activated-receptors (PPARs) are a family of transcription 
factors capable of mediating dietary and metabolic regulation of gene expression.  
The PPARs are a subfamily of nuclear hormone receptors composed of three 
isotypes: F, G, and =. All three PPARs are expressed in ovarian tissue from several 
mammalian species, including mice, pigs, sheep, cows, and humans.  Our laboratory 
has shown that in the rat, PPAR= is differentially expressed during the ovarian cycle, 
and that it does not play a major role in luteal progesterone production.  This differs 
from work done in cattle, where agonists of PPAR= stimulated progesterone 
production from cultured mid-cycle luteal cells [1]. To investigate if the disparate role 
of PPAR= in luteal progesterone production between rats and cows was due to 
differences in luteal formation/function, and/or a change in  expression of mRNA or 
protein for PPAR= during the estrous cycle, the following study was conducted.  
Antral follicles and corpora lutea were collected from cycling heifers (n=3) on the 
following days post-ovulation: 4; 12; 12, 24 hours post-PGF2F to initiate luteal 
regression; and 17.  Messenger RNA and protein corresponding to PPAR= were 
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measured via RT-PCR and western immunoblot, respectively.  Pieces of CL were 
also cultured in defined media in the presence and absence of agonists (PGJ2 and 
ciglitazone), and an antagonist (GW-9662) of PPAR=. Media were collected after 24 
hours and analyzed for progesterone by RIA.  Expression of mRNA for PPAR= in 
follicular and luteal tissue remained relatively steady throughout the cycle.  However, 
protein for PPAR= was lower in luteal tissue collected on day 12, 24 hours post-
PGF2F, and on day 17, compared to tissue collected from untreated heifers on day 12 
(p < 0.05).  Cultured luteal tissue collected on day 17 and treated with a high dose of 
ciglitazone (25 Um), secreted less progesterone than controls (p < 0.05).  The 
relatively steady expression pattern of PPAR= during formation of the CL, as well as 
the ability of PPAR= agonists to affect progesterone production, indicate that this 
transcription factor may play a role in luteal formation and/or function in cattle.   
 
INTRODUCTION 
The reproductive efficiency of dairy cows has decreased from 65% in 1951 to 
40% in 1996 (reviewed in [2]).  In addition to lost production, poor reproductive 
performance negatively affects the dairy industry by decreasing the efficiency of 
producing replacement heifers.  One reason for the decline in fertility is the 
development of a negative energy balance caused by the increased nutritional 
requirements of lactation (reviewed in [3]; [2]).  Even with improved diet, a negative 
energy balance is difficult to avoid in lactating cows.  One aspect of female fertility 
affected by nutrition is ovarian function.  Dietary factors, such as fatty acids and their 
metabolites, can influence ovarian biology because of the role they play in processes 
such as cell signaling and steroidogenesis (reviewed in [4]).  Fatty acids may also 
regulate ovarian gene expression by binding to a family of transcription factors, the 
peroxisome proliferator activated-receptors. 
The peroxisome proliferator activated-receptors (PPARs) are a sub-family of 
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nuclear hormone receptors comprised of three isotypes: F, G, and =. The PPARs are 
involved in numerous processes critical to ovarian function such as angiogenesis, 
steroidogenesis, inflammation, tissue remodeling, and lipid metabolism (reviewed in 
[5]).  Fatty acids and prostaglandins are two compounds commonly found in the 
ovary that are endogenous ligands of the PPARs [6;7].  Both molecules are also 
involved in the regulation of cellular energy production and luteal formation and 
function, respectively.  Exogenous ligands of the PPARs, such as plasticizers, 
phytoestrogens, and pharmaceuticals (thiazolidnediones, fibrates) also impact ovarian 
function (reviewed in [8]; [5]).  Therefore, the PPARs may mediate the effects of diet 
and metabolic status, as well as exposure to environmental factors, on ovarian 
function. 
In the rat, all three PPAR isotypes are expressed in the ovary, but only PPAR=
is differentially expressed during the ovarian cycle [9; 10].  Expression of PPAR= is 
primarily localized to granulosa cells [9; 11].  It is also expressed in luteal tissue, but 
at a much lower level [9 - 11].  The expression of PPAR= in the rat is down-regulated 
by the luteinizing hormone (LH) surge [12], and is inversely related to the expression 
of P450 side chain cleavage [12; 29].  Cui et al. (2003) reported generating a mouse 
exhibiting tissue specific disruption of PPAR= in the ovary, mammary epithelium, 
and B and T cells.  Mice with expression of PPAR= specifically disrupted in the ovary 
were either infertile [13] or subfertile [14], indicating that PPAR= may play a major 
role in fertility [15].   
In 1997, PPAR= was cloned from cows and identified in a variety of bovine 
tissues, including the ovary [16].  Subsequent studies reported that PPAR= is involved 
in cell cycle maintenance and progesterone production from mid-cycle CL [1;17].  To 
our knowledge, detection of PPARF and PPARG in the bovine ovary has not been 
reported. 
Because PPAR= has the potential to mediate the effects of nutrition on ovarian 
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gene expression, the following studies were conducted to investigate the role of 
PPAR= in progesterone production in the bovine.  The expression of PPAR= in 
ovarian tissue throughout the estrous cycle was determined, and the impact of PPAR=
on luteal progesterone production was studied to determine if its effects were 
dependent upon the stage of the cycle.  Additionally, the expression of PPARF and 
PPARG in several major bovine organs was determined. 
 
METHODS AND MATERIALS 
Tissue Collection 
Study 1. To examine the expression pattern of the PPARs in the bovine, 
tissue samples from the ovary, liver, lung, heart, spleen, and kidney were collected 
from Angus cows or heifers (n=3) immediately following slaughter.  Whole follicles 
and corpora lutea were dissected from the ovary.  Tissue samples were snap frozen 
and stored at -70°C until processed for isolation of protein or total RNA.  
 
Study 2. The pattern of expression and role of PPAR= in the bovine ovary 
was investigated by collecting ovaries from cycling Angus heifers.  Ovarian dynamics 
were monitored in yearling heifers by transrectal ultrasonagraphy.  Waves of 
follicular development, and growth and regression of the CL, were recorded by 
measuring two perpendicular diameters of follicular and luteal structures larger than 5 
mm.  Ovaries were collected on days 4 (n=3), 12 (n=6), and 17 (n=3) post ovulation.  
Day 1 was defined as the first day the ovulatory-sized follicle was no longer 
observed.  These collection times correspond to early, mid, and late stages of the 
luteal phase.  To study both functional and regressed luteal tissue, on day 11 of the 
estrous cycle heifers were randomly divided into two groups (n=3/group).  One group 
received 25 mg of PGF2F (Lutylase, Pharmacia, Peapack, NJ), and their ovaries were 
collected 24 hours later (d12 post-PGF2F).  The second group served as untreated 
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controls and had their ovaries removed on d12.  Ovaries were removed from all 
animals by a flank incision, immediately placed in transfer media [minimum essential 
medium, (Gibco, Carlsbad, CA), 2.2% g/L NaHCO3 (Sigma Aldrich, St. Louis), 50 
IU/ml penicillin, 50 Ug/ml streptomycin] and transported to the laboratory.  Luteal 
and follicular tissues were dissected from the ovary within 30 minutes of surgery.  
Luteal tissue was divided and cultured in vitro as described below, or snap frozen and 
stored at -70°C for future analysis.  Follicles ranging in size from 2 to 15 mm were 
cleaned of stromal tissue and snap frozen for future analysis.  Blood was collected 
from the coxygeal vein of all heifers prior to surgery.  In addition, blood was 
collected from heifers on d11 immediately prior to injection with Lutalyse, and on 
d16 from animals that were to have tissue collected on d17.  Serum was stored at -
20°C until the concentration of progesterone was measured by RIA.  All procedures 
involving animals were approved prior to use by Iowa State University’s Institutional 
Animal Care and Use Committee. 
 
Tissue Analyses 
Western blotting. Total protein was isolated from non-cultured, frozen tissue 
samples by homogenization in 1x sodium dodecyl sulfate buffer (SDS, Sigma 
Aldrich) and quantified with the Bio-Rad DC Protein Assay (Hercules, CA) as 
described by the manufacturer.  Proteins (10 Ug) were size separated by 
electrophoresis through a 10% poly-acrylamide gel, and subsequently transferred to a 
nitrocellulose membrane (Amersham, Piscataway, NJ).  Membranes were blocked 
overnight with 5% non-fat dried skim milk in phosphate buffered saline (PBS, pH = 
7.2) at 4°C and subsequently incubated with a rabbit anti-PPAR= antibody (ABR, 
Golden, CO, at a 1:2000 dilution) for 1 hour at room temperature.  After washing in 
PBS, membranes were incubated with a biotinylated mouse anti-rabbit antibody 
(1:2000, Amersham, Piscataway, NJ) at room temperature for 1 hour.  The protein of 
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interest was visualized using an ECL detection kit (Amersham, Piscataway, NJ).  
Membranes were exposed to x-ray film (Kodak, Rochester, NY) for increasing 
lengths of time to ensure linearity of the signal, and subsequently stripped of 
conjugates with a G-mercaptoethanol buffer (100 mM G-mercaptoethanol in TBST, 30 
min, 42°C with rocking) and re-probed with an antibody against G-actin (Biomol, 
Plymouth Meeting, PA).  Densitometry was performed using the SpotDenso program 
(Alpha Innotech, San Leandro, CA) to establish the PPAR=:G-actin ratio for each 
sample. 
Semi-quantitative RT-PCR.  Total RNA was extracted from frozen tissues 
with TRIZOL reagent according to the manufacture’s instructions.  RNA quality was 
assessed by formaldehyde gel electrophoresis.  Complementary DNA was 
synthesized from 2 Ug of total RNA with Oligo dT in 20 Ul reactions as 
recommended for SuperScript II reverse transcriptase.  Following quantification of 
cDNA by spectrophotometry, transcripts for the PPARs and the housekeeping gene, 
GADPH, were amplified by PCR using isotype specific primers (Table 3-1).  Each 25 
Ul reaction amplifying a PPAR isotype consisted of 1 UM of each primer, 2.5 mM 
MgCl2, 200 UM dNTPs, 1X PCR buffer, and 1 U Taq-polymerase.  To amplify 
GADPH, 0.0125 UM of the forward and reverse primers were added.  Reaction 
conditions were as follows: PPARF: 30 cycles at 94°C for 40 sec, 55°C for 1 min, and 
72°C for 1 min; PPARG: 30 cycles at 94°C for 60 sec, 69°C for 60 sec, and 72°C for 
120 sec; and PPAR= and GADPH, 35 cycles at 95°C for 30 sec, 55°C for 30 sec, and 
72°C for 90 sec.  Amplified products were separated by gel electrophoresis through 
2% agarose gels containing ethidium bromide.  PCR products were sequenced to 
validate amplification of the desired transcript.  Densitometry was performed using 
Alpha Innotech SpotDenso software and levels of mRNA for the PPARs were 
standardized to levels of mRNA for GADPH/sample.  All reagents used for analysis 
of RNA were purchased from Invitrogen (Carlsbad, CA), with the exception of the 
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Taq-polymerase (Bioline, Randolph, MA).  Primers were synthesized by Integrated 
DNA Technologies (Coralville, IA).   
To ensure the semi-quantitative nature of the assay, the amount of cDNA used 
as a starting template for each PCR reaction and the number of cycles per program 
were validated.  Densitometry was performed on PCR reactions every 5 cycles 
starting at cycle 20 and ending at cycle 50.  The number of cycles used in each PCR 
program was selected from within the range that yielded output in a linear 
relationship to input, as determined by densitometry.  Similarly, the amount of cDNA 
used was determined by selecting from within the linear range of output paralleling 
changing concentrations of cDNA in the reaction.   
Tissue Culture. Luteal tissue was divided into 1 x 3 mm pieces and cultured 
in duplicate with 500 Ul of media (minimum essential medium, 2.2% g/L NaHCO3,
6.5 mg/ml HEPES, 50 IU/ml penicillin, 50 Ug/ml streptomycin, 0.05% g/L 
transferrin, 4.0 mg/ml cortisol, and 0.1% g/L insulin), with the following treatments: 
control (DMSO), PGJ2 (5 or 65 UM), ciglitazone (5 or 25 UM), GW-9662 (0.2  or 2.0 
ng/ml), or LH (100 ng/ml).  Tissues were incubated in a humidified 5% CO2/95% air 
environment for 24 hours at 37° C.  After culture, media were collected and stored at 
-20°C until analyzed for progesterone by RIA.  Tissues were weighed and frozen at -
70°C.  Total RNA was extracted and levels of mRNA for PPAR= determined by 
semi-quantitative RT-PCR as described above.  Reagents used for tissue culture were 
obtained from Sigma Aldrich (St. Louis, MO).  Compounds used to treat cultured 
cells (PGJ2, ciglitazone, and GW-9662) were purchased from Biomol (Plymouth 
Meeting, PA).  Luteinizing hormone (LH) was provided by A.F. Parlow from the 
National Hormone Peptide Program Torrence, CA.   
Radioimmunoassay.  Concentrations of progesterone in media and serum 
were determined by direct radioimmunoassay (DPC, Los Angeles, CA) as previously 
described [9].  The inter- and intra-assay coefficients of variations were 14.2% and 
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5.6%, respectively.  Concentrations of progesterone in the conditioned media were 
standardized by tissue weight/well. 
Statistical analysis.  Data to be statistically analyzed were tested for normal 
distribution prior to analysis.  Differences in mRNA and protein corresponding to 
PPAR= between various tissues were determined by one-way ANOVA (SAS 9.0, 
SAS Institute, Cary, NC).  Concentrations of progesterone in conditioned culture 
media were analyzed by two-way ANOVA, followed by post-hoc analyses with 
Tukey’s HSD and Duncan’s test.  A p value < 0.05 was considered significantly 
different.   
RESULTS 
Study 1. To create expression profiles for all PPAR isotypes, semi-
quantitative RT-PCR was performed on mRNA extracted from major organs of the 
cow.  Expression of PPARF was found in all tissues screened (Figure 3-1).  Heart and 
liver exhibited a high level of expression of PPARF while lung tissue exhibited a low 
level.  The expression of mRNA for PPARF was intermediate in the follicle, CL, 
spleen, and kidney.   
The transcript for PPARG was also expressed in all tissues analyzed.  High 
expression was detected in the CL, kidney, and spleen (Figure 3-2).  Heart, liver, and 
follicular tissue expressed intermediate levels of mRNA for PPARG, with the lung 
exhibiting low expression. 
Liver and heart expressed low levels of mRNA for PPAR=, whereas lung 
exhibited high expression (Figure 3-3).  PPAR= expression was also detected in the 
spleen and kidney.  Regarding protein corresponding to PPAR=, the kidney and 
spleen exhibited high expression of PPAR= (Figure 3-4). 
 
Study 2. To determine if PPAR= was differentially expressed during the 
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bovine ovarian cycle, follicular and luteal tissues were collected from heifers at 
defined times throughout the cycle.  Ovaries were collected from cycling heifers on 
days 4, 12, day 12 after PGF2F treatment, and 17 post-ovulation.  Luteal regression 
was verified in heifers treated with PGF2F by measuring progesterone in serum 
collected before, and 24 hours after treatment.  Luteolysis was defined as circulating 
concentrations of progesterone measuring less than 1.0 ng/ml.  Prior to the 
administration of PGF2F on day 11 post-ovulation, progesterone measured 6.805 ± 
1.51 ng/ml.  On day 12, 24 hours post PGF2F, progesterone had declined to 0.57 ± 
0.15 ng/ml.  Luteolysis was further validated by comparing the amount of 
progesterone secreted over 24 hours in culture by untreated luteal tissue collected 
from control heifers on day 12 post-ovulation, and heifers treated with PGF2F. As 
shown in Table 3-2, luteal tissue collected on day 12, 24 hours post-PGF2F secreted 
significantly less progesterone in vitro than tissue from control animals (p=0.0023).  
Serum collected from heifers whose ovaries were removed on day 17 post ovulation 
had 3.2 ± 1.75 ng/ml of circulating progesterone.  Only one of the three heifers in that 
group had undergone luteolysis (serum progesterone = 0.92 ng/ml). 
Transcripts of PPAR were detected in ovarian tissues at all time points 
investigated (Figures 3-5 and 3-6).  The expression of mRNA for PPAR= in follicular 
tissue was comparable between small, medium, and large follicles (Figure 3-5).  
Similar levels of mRNA for PPAR= were also observed in luteal tissue collected on 
days 4, 12, and 17 (Figure 3-6).  However, luteal tissue collected on day 12 from both 
control heifers and those that received PGF2F tended to have greater levels of mRNA 
for PPAR= than CL collected on day 17 (p = 0.066, Figure 3-6).  Relative amounts of 
protein corresponding to PPAR= were greater in luteal tissue collected on days 4 and 
12 of the cycle, compared with levels in tissue collected on day 17 post-ovulation 
figure (Figure 3-7).  Interestingly, in luteal tissue collected on d12 post-ovulation, 
protein corresponding to PPAR= was lower after the administration of PGF2F
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compared with tissues collected from untreated animals on d12 (p < 0.05). 
The impact of PPAR= on progesterone production was investigated in mid-
cycle and late stage luteal tissue.  Corpora lutea collected from heifers on days 12 and 
17 were cultured with agonists (PGJ2 or ciglitazone) and an antagonist (GW-9662) of 
PPAR=. Luteal tissue collected from animals on day 12 post-ovulation responded to 
treatment with LH by secreting more progesterone compared to untreated controls (p 
< 0.05; Figure 3-8).  Administration of either agonist or the antagonist of PPAR= to 
luteal tissue collected on day 12, with or without the administration of PGF2F, had no 
effect on progesterone secretion (Figure 3-8 and Figure 3-9).  However, treatment 
with 25 UM ciglitazone significantly decreased progesterone production by cultured 
luteal tissue collected on day 17 post-ovulation (p < 0.05; Figure 3-10).  To determine 
if reduced secretion of progesterone in response to ciglitazone was due to toxicity, 
cell viability was investigated by assessing the quality of RNA extracted from 
cultured tissues.  Total RNA was separated by electrophoresis through a 
formaldehyde-agarose gel.  The integrity of the 28S and 18S ribosomal subunits 
within or between RNA samples from ciglitazone treated and control tissues, were 
not different (data not shown).  These findings indicate that the inhibitory effect of 
ciglitazone on progesterone secretion was not due to a negative effect on cell viability  
 
DISCUSSION 
Since their initial isolation from mouse hepatocytes [18], the PPARs have 
been implicated as regulators of numerous metabolic and physiological processes, 
such as fatty acid and lipid metabolism, inflammation, cell cycle progression, 
steroidogenesis, and angiogenesis (reviewed in [4]).  In the rat, previous reports have 
established that each PPAR isotype is differentially expressed in a tissue specific 
manner [19].  To our knowledge, a tissue screen of major organs in the bovine has 
only been conducted for PPAR= [16].  Data presented in this study report the 
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expression profiles of mRNA for PPARF and PPARG, and for mRNA and protein 
corresponding to PPAR=, in bovine tissues.  The findings presented herein indicate 
that each member of the PPAR family of transcription factors is differentially 
expressed in bovine tissues and that the expression patterns correspond with 
previously reported isotype-specific functions.   
One primary role of PPARF is in the regulation of lipid metabolism via the G-
oxidation of fatty acids in the liver [20].  The high expression of mRNA for PPARF
in the liver observed in the current study is similar to trends observed in the rat [19], 
and human [21].  Expression of mRNA for PPARF in the bovine heart was also found 
to be high.  This tissue has a high rate of fatty acid metabolism for energy production.  
PPARF also plays a role in regulating the duration of inflammatory responses, a 
process that is critical to maintain healthy cardiac tissue [22].
The ubiquitous expression of PPARG agrees with findings in other species 
[19; 23].  The high expression of PPARG in the bovine CL corresponds with 
expression in the rat [10].  PPARG has been implicated in both angiogenesis and 
tissue remodeling [24] which are important processes for the development and of 
follicles and luteal tissue.  Expression of mRNA for PPARG in the bovine kidney was 
also high, similar to expression in the rat [19]. 
The findings presented here on results of screening bovine tissues for PPAR=
expand data previously reported by Sundvold et al. (1997) [16].  The relatively low 
expression of mRNA for PPAR= in the liver, heart, and kidney is similar to the 
expression profile in the rat [19].  Expression of mRNA for PPAR= in the spleen of 
the bovine corresponds to the level of expression in the rat [19], where it is involved 
in the inhibition of anti-inflammatory agents NFY-B and TNFF [25].  In the current 
study, high expression of mRNA for PPAR= was detected in the lung.  However, the 
expression of protein for PPAR= was low in the lung.  Because an inverse 
relationship between levels of mRNA and protein for PPAR= was not observed in 
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other tissues, there may be specific processing of PPAR= that occurs in the lung.  
Recent reports addressing the presence of PPAR= in rodent lung tissue have revealed 
that PPAR= is needed for the formation of normal lung tissue [26] and also plays a 
role in reducing pulmonary inflammation [27].   
In the ovary, luteal tissue collected on day 12 post PGF2F administration 
expressed the same amount of mRNA for PPAR= as tissue collected on day 12 that 
had not undergone luteolysis.  A decrease of PPAR= protein was observed after 
administration of PGF2F, unlike the expression of the corresponding mRNA that 
remained relatively high.  While the reasons for such a discrepancy between levels of 
mRNA and protein are unclear, one hypothesis put forth by the authors is a potential 
difference in the rate of turn-over for mRNA versus protein, dependent upon the age 
of the luteal tissue.   
A previous study by Löhrke et al. (1998) reported that when treated with a 
PPAR agonist, mid-cycle luteal cells increased progesterone secretion in vitro. Data 
collected from the current study demonstrate no effect of agonists of PPAR= on the 
production of progesterone from mid-cycle luteal tissue.  One possible reason for the 
discrepancy between the study by Lörhke et al. and the data presented from the 
current study, is the method used to culture tissue.  The current experiments cultured 
intact luteal tissue, whereas the previous study cultured dispersed cells.  Tissue slices 
were chosen for the current study because maintenance of cell to cell contact within 
bovine luteal tissue provides a more accurate model of in vivo luteal function.  
Previous study of luteal tissue has found that cell to cell contact influences hormone 
production [38].  When cell contact was not maintained, hormone production from 
luteal cells decreased [28].  Also of interest is the fact that treatment of luteal tissue 
collected on day 17 post-ovulation with the PPAR= agonist, ciglitazone, inhibited 
progesterone production.  However, a similar effect when culturing luteal tissue 
collected on day 12 post PGF2F was not observed.  One potential reason for this 
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discrepancy could be the mixed physiological state of the heifers on day 17 post-
ovulation when the tissue was collected.  Only one of the animals had undergone 
luteolysis by day 17 post-ovulation, and therefore might have responded differently to 
the treatments in vitro.
The data presented in this study support the hypothesis that PPAR= plays a 
role in regulating ovarian function.  Production of progesterone is influenced by the 
activation of PPAR= depending upon the stage of the ovarian cycle.  The relatively 
high levels of expression of PPAR= during the early and mid-luteal phase suggests 
that this transcription factor might also play a role in the formation and function of 
the CL.  In addition, the presence of both PPARs F and G in the bovine ovary indicate 
that they may also regulate ovarian gene expression.  Further study of the PPARs in 
the ovary is important to determine what genes they regulate and how they impact 
ovarian function.  Such information may elucidate the mechanisms behind the effects 
of diet and environmental factors on female fertility.     
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Figure 3-1.  Representative autoradiograph depicting the expression of mRNA for 
PPARF in select bovine tissues.  Tissues were collected (n=3) and analyzed by RT-
PCR as described in the Materials and Methods.  CL d4 = corpus luteum collected on 
day 4 post-ovulation.  Lrg Fol = large ovarian follicle > 10 mm in diameter. 
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Figure 3-2.  Expression of mRNA for PPARG in select bovine tissues.  Tissues were 
collected (n=3) and analyzed by RT-PCR as described in the Materials and Methods.  
CL d4 = corpus luteum collected on day 4 post-ovulation.  Lrg Fol = large ovarian 
follicle > 10 mm in diameter. 
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Figure 3-3. Relative expression of mRNA for PPAR= in selected bovine tissues.  
Tissues were collected (n=3) and analyzed by RT-PCR as described in the Materials 
and Methods.  Data are presented as means ±S.E.M. 
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Figure 3-4.  Representative autoradiograph of the amount of PPAR= protein in select 
bovine tissues.  Tissues were analyzed by western immunoblot as described in the 
Methods and Materials.  h: heart; k: kidney; li: liver; s: spleen, lu: lung. 
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Figure 3-5.  Relative levels of mRNA for PPAR= in bovine follicular tissue.  
Follicular tissues were collected and analyzed by RT-PCR as described in Methods 
and Materials.  Data are presented as means ± S.E.M 
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Figure 3-6.  Relative levels of mRNA for PPAR= in bovine luteal tissue.  Tissues 
were collected (n=3) and analyzed by RT-PCR as described in Methods and 
Materials.  d4: day 4 post ovulation; d12: day 12 post ovulation; d17: day 17 post 
ovulation; d12 post PG: administration of PGF2F on day 11, 24 hours prior to tissue 
collection.  Data are presented as means ± S.E.M. 
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Figure 3-7.  Relative levels of PPAR= protein in bovine luteal tissues.  Tissues were 
collected (n=3) and analyzed by western blot as described in Methods and Materials.  
Data are presented as means ± S.E.M .  Bars with no common superscripts are 
significantly different (p < 0.05).  d4: day 4 post ovulation; d12: day 12 post 
ovulation; d17: day 17 post ovulation; d12 post PG: day 12 post ovulation with 
administration of PGF2F 24 hours prior to collection.   
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Figure 3-8.  Secretion of progesterone over 24 hours in vitro by pieces of luteal tissue 
collected on day 12 post-ovulation (n=3).  Bars with  indicate significant difference 
from control (p < 0.05).  Cig = ciglitazone GW = GW 9662.  Data are presented as 
means ± S.E.M.  Control samples produced 43.78 ± 3.33 ng/ml of progesterone.   
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Figure 3-9.  Secretion of progesterone over 24 hours in culture by pieces of luteal 
tissue collected on day 12 post PGF2a (n=3).  Cig = ciglitazone GW = GW 9662.  
Data are presented as means ± S.E.M.  Control samples produced 16.65 ± 0.91 ng/ml 
of progesterone.   
 
52
0
50
100
150
LH  PGJ2 
5 µm
PGJ2
65 µm
 Cig    
5 µm
 Cig   
25 µm
GW  
0.1 µg
GW  
1.0 µg
Pr
og
es
te
ro
ne
pr
od
uc
tio
n
as
%
of
C
on
tr
ol

Figure 3-10.  Secretion of progesterone over 24 hours in culture by pieces of luteal 
tissue collected on day 17 post-ovulation (n=3).  Bars with  indicate significant 
difference from control (p < 0.05).  Cig = ciglitazone GW = GW 9662.  Data are 
presented as means ± S.E.M.  Control samples produced 64.51 ± 32.42 ng/ml of 
progesterone.   
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Primer Sequence Product Size Reference 
bPPAR= F GAC TTG AAC GAC CAA GTA ACT C 490 bp 
bPPAR= R CTC TGC TAA TAC AAG TCC TTG TAG  
Huff M., 
personal 
communication
bPPARF F GGA TCA GAT GGC TCC GTT ATT ACA G 925 bp 
bPPARF R GCT CCA GTG CAT TGA ACT TCA TTG  
Balageur et al., 
2005 
bPPARG F CAC TCT CAC TGC TGG ACA A 815 bp 
bPPARG R TGC GGT TCT TCT TCT GGA TT  
Banerjee and 
Komar, 
unpublished 
bGADPH F TGT TCC AGT ATG ATT CCA CCC 850 bp 
bGAPDH R TCC ACC ACC CTG TTG CTG TA  
Tsai et al., 
1996 
 
Table 3-1. Primer sequences utilized for PCR. F = forward; R = reverse. 
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Concentration of progesterone secreted 
over 24 hours in vitro (ng/ml) 
Treatment Group Mean ±SEM 
Day 12 Control 43.78 ± 3.33** 
Day 12 post-PGF2F 16.65 ± 0.91 
 
Table 3-2. Concentrations of progesterone in culture media from luteal tissue 
collected from heifers on d12 post-ovulation.  One group (n=3) received PGF2F on 
day 11, 24 hours prior to ovariectomy; the second group (n=3) served as untreated 
controls.  Concentrations of progesterone are presented as means ± SEM.  ** 
indicates significant difference (p<0.05). 
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CHAPTER 4.  GENERAL CONCLUSIONS 
 
DISCUSSION AND CONCLUSION 
Since their initial discovery in 1990, a large body of literature has been 
generated from studying the functions of the PPARs.  Their role in several tissues and 
physiological processes has been identified, but very little is known regarding their 
impact on ovarian biology.  Many of the processes regulated by the PPARs are 
important for ovarian function, and both endogenous and exogenous ligands for the 
PPARs are known to affect ovarian function.  Therefore, the studies described herein 
were conducted to investigate the role of PPARs in the ovary using the cow as an 
experimental model. 
 The study presented in Chapter 3 provides important insight into PPAR 
expression in the bovine ovary.  This study complements previous work in cattle [1-3] 
and other ruminants [4] which identified PPAR= in ovarian tissue, specifically 
granulosa cells [2] and the corpus luteum [2-4].  Our findings extend those previously 
published by determining the expression of both mRNA and protein for PPAR=
throughout the estrous cycle, and is the first, to our knowledge, to detect the other two 
PPAR isotypes, F and G, in the bovine ovary.  We report that the expression of 
PPAR= protein is dependent upon the stage of the CL, with high expression in the 
early and mid-luteal phase, suggesting a role in the formation and/or function of luteal 
tissue.   
Functional analysis of PPAR= in cultured luteal tissue illustrated a significant 
decrease in progesterone secretion when the tissue was treated with the PPAR=
agonist, ciglitazone.  The finding that supposed activation of PPAR= affects 
progesterone production near the end of the ovarian cycle indicates that PPAR= may 
also regulate luteal demise.  Further study is needed to determine how the expression 
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of PPAR= is regulated in the ovary, and the mechanisms by which it influences luteal 
tissue.  Future studies using the bovine model will advance our understanding of the 
regulatory factors driving ovarian function which is particularly important for 
production animals in order to maintain and/or increase reproductive efficiency. 
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APPENDIX.  GENERATION OF MICE WITH THE EXPRESSION OF PPAR2
SELECTIVELY DISRUPTED IN THE OVARY 
 
Lacey J. Luense and Carolyn M. Komar 
 
ABSTRACT 
Peroxisome proliferator activated-receptor = (PPAR=) is a transcription factor 
involved in regulating many physiological processes, including lipid metabolism, 
inflammation, steroidogenesis, and angiogenesis.  These events play an important role 
in normal ovarian function.  Previous studies have determined that PPAR= is 
differentially expressed in the ovary.  However, the role PPAR= plays in ovarian 
function has yet to be completely elucidated.  Lack of viable PPAR= knock-out mice 
has made investigating the role of PPAR= in female fertility difficult.  Therefore, to 
determine the role of PPAR= in ovarian biology, a mouse line with tissue specific 
disruption of PPAR= in the ovary was generated via cre/loxP recombination.  The 
effect of reducing PPAR= in the ovary on reproduction in mice was investigated by 
characterizing various breeding parameters such as number of pups per litter and days 
per litter (total days mated/number of litters).  Mice with PPAR= disrupted in the 
ovary had, on average, smaller litters than wild-type litter mates.  The establishment 
of mice with disruption of PPAR= in the ovary is a novel model for studying of the 
role of PPAR= in ovarian gene expression and function. 
 
INTRODUCTION 
Peroxisome proliferator-activated receptor = (PPAR=) is a member of the 
nuclear hormone receptor superfamily.  It was originally identified as an adipocyte 
differentiation factor [1], and has since been found to regulate a number of cellular 
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processes including steroidogenesis, inflammation, tissue remodeling, and 
angiogenesis (reviewed in [2]).  These are critical events for normal ovarian function.  
PPAR= has been detected in ovarian tissue from the rat [3], bovine [4], pig [5], human 
[6], and sheep [7].  Expression of PPAR= in the rat ovary is primarily localized to 
granulosa cells of the follicle, although it is also expressed at lower levels in theca 
cells and the corpus luteum [8-11].  A study conducted with sheep also found high 
expression of PPAR= in granulosa cells with lower expression in the CL [7].  In the 
bovine, PPAR has been reported to be expressed in the CL [12].  
Investigation into the function of PPAR= in ovarian follicles has found that in 
both the rat and sheep, agonists of PPAR= inhibit the proliferation of granulosa cells 
[13; 7].  PPAR= has also been reported to play a role in progesterone production from 
granulosa cells in humans [6] and eCG primed rats [14; 10], as well as, in luteal tissue 
from the bovine [12].  In the bovine, secretion of progesterone from dispersed luteal 
cells, cultured for 24 hours in the presence of a PPAR= agonist, was greater than the 
concentration secreted from non-treated tissue [12].  However, recent findings from 
our laboratory using cultured luteal tissue from various stage of the cycle found that 
progesterone production decreased when treated with a PPAR= agonist [15].   
A study by Cui et al. (2003) demonstrated that PPAR= plays an important role 
in female fertility [16].  In mice with expression of PPAR= disrupted in the ovary, 
mammary tissue, and B and T cells, fertility was decreased [16].  When expression of 
PPAR= was diminished, mice had fewer pups/litter and took longer to conceive than 
wild-type litter mates with intact PPAR= expression [16]. Because the expression of 
PPAR= was not disrupted in the uterus of these animals, the authors concluded that 
the lesion causing reduced fertility resided in the ovary.  Previous attempts to 
establish a PPAR= knock-out mouse were successful in generating progeny with 
expression of PPAR= ablated, however these mutants were not viable due to the 
necessity of PPAR= in placental development [17].  Therefore, to facilitate 
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investigating the role of PPAR= in ovarian function, we have used cre/loxP 
recombination to generate mice with selective disruption of PPAR= in the gonad.   
 
METHODS AND MATERIALS 
Generation of gonad-specific PPAR2 null mice.  All procedures involving 
mice were approved prior to use by Iowa State University’s Institutional Animal Care 
and Use Committee.  Mice homozygous for loxP insertions that flanked exon 2 of 
PPAR= (PPAR=fl/fl mice were generously donated by Dr. Frank J. Gonzalez [18]) 
were crossed with mice heterozygous for Cre recombinase knocked into the anti-
Mullerian hormone receptor 2 locus (Amhr2cre/wt ; generously provided by Dr. 
Richard R. Behringer [19]).  F1 progeny were genotyped, and PPAR=fl/wt;Amhr2cre/wt 
mice were mated to founder PPAR=fl/fl mice to obtain animals homozygous for the 
floxed PPAR= allele and heterozygous for Cre recombinase (PPAR=fl/fl;Amhr2cre/wt).  
The resulting progeny (PPAR=fl/fl;Amhr2cre/wt) were backcrossed to the PPAR=fl/fl 
founder line for six generations to insure a highly conserved genetic background 
(Figure 4-1).  
For determining the degree to which the PPAR was excised in ovarian tissue 
from PPAR=fl/fl;Amhr2cre/wt versus PPAR=fl/wt;Amhr2cre/wt mice, ovaries were 
collected from sexually mature females.  Tissues were immediately frozen at -70°C 
and reserved for nucleic acid extraction. 
The effect of reducing the expression of PPAR= in the ovary on female 
fertility was investigated by establishing the following matings involving F2 mice: 
PPAR=fl/fl;Amhr2cre/wt and PPAR=fl/wt;Amhr2cre/wt females were crossed with males 
heterozygous for Cre and either hetero- or homozygous for the PPAR= floxed allele.  
Breeding data were collected over the course of several months and the following 
parameters for each dam were recorded: total number of days mated, number of 
litters, and number of pups born per litter.  The mean number of pups per litter and 
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number of days between litters were used to assess female reproductive fitness.  To 
determine the number of days between litters for each female, the total number of 
days mated was divided by the total number of litters.   
DNA Extraction and Genotyping. Tail biopsies, approximately 0.5 cm long, 
were collected from mice 9 to 11 days old.  Tissues were dissolved in 465 Ul of tail 
extraction buffer (50 mM Tris pH 7.5, 100 mM EDTA, 0.5% SDS, and 650 mg/ml 
proteinase K) by incubating overnight with rotation at 55°C.  The following day, 250 
Ul of dissolved tissue solution were added to an equal amount of 
phenol:chloroform:iso-amyl alcohol (25:24:1; Invitrogen), mixed vigorously, and 
centrifuged at 15,000 rpm for 5 minutes at 4°C.  The supernatant was removed and 
extracted twice with phenol:chloroform.  Following the final extraction, the aqueous 
portion was removed and added to 1 ml of cold 100% ethyl alcohol to precipitate the 
DNA.  Samples were centrifuged at 15,000 rpm for 15 minutes at 4°C prior to 
supernatant aspiration and rinsing of the pelleted DNA with room temperature 70% 
ethyl alcohol.  The DNA was then vortexed and centrifuged at 15,000 rpm for 5 
minutes at 4°C, the ethyl alcohol was discarded, and the pellets allowed to air dry for 
5 to 10 minutes.  The pelleted DNA was resuspended by adding 100 Ul of Tris-Cl 
EDTA (TE) and incubated at 37°C overnight.  Concentrations of DNA were 
quantified by spectrophotometry. Samples were diluted to a concentration of 10 ng/Ul
and stored at -70°C for future use.   
Genotypes were determined by PCR at both the PPAR= and Amhr2 loci. The 
following primers were used to amplify the wild type, floxed, and null alleles for 
PPAR=: F, 5’-ctc caa tgt tct caa act tac-3’; Rev1, 5’-gat gag tca tgt aag ttg acc-3’; 
Rev2, 5’-gta ttc tat ggc ttc cag tgc-3’ [16].  PCR reactions consisted of 2.5 mM 
MgCl2, 1X PCR buffer, 10 UM of each primer, 10 mM dNTPs, 10X bovine serum 
albumin, 1 U Taq polymerase (Bioline, Boston), and 50 ng DNA in 25 Ul reactions.  
For amplification, 35 cycles were used at 94°C for 30 seconds, 60°C for 30 seconds, 
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and 72°C for 90 seconds, with an initial denaturation at 94°C for 2 minutes and a final 
extension for 5 minutes at 72°C.  Insertion of Cre recombinase into the gene encoding 
Amhr2 was determined by amplification of genomic DNA with the primers: Cre1, 5’-
gcg gtc tgg cag taa aaa cta tc-3’; Cre2, 5’gtg aaa cag cat tgc tgt cac tt-3’ (sequences 
from Jackson Laboratories, Bar Harbor, ME).  Amplified PCR products were 
separated by electrophoresis through a 2% agarose gel.  PCR products representing 
wild-type alleles of PPAR= produced a 225 bp fragment, flox flanked PPAR= alleles a 
275 bp fragment, and the null PPAR= allele produced a 400 bp fragment.  The 
primers for Cre recombinase amplified a 100 bp fragment, while no product was 
amplified if only the Amhr2 wild-type allele was present.  To verify that the reaction 
worked, a multiplex PCR reaction using the primers to amplify the Cre recombinase 
gene and the housekeeping gene interleukin-2 (Il-2) was used.  If the Cre recombinase 
gene was absent and no product was amplified, the presence of an amplified Il-2 gene 
product indicated that a successful PCR reaction had occurred. (Il-2F, 5’-cta ggc cac 
aga att gaa afa tct-3’; Il-2R, 5’-gta ggt gga aat tct agc atc atc c-3’; 324 bp; Jackson 
Laboratories). 
Assessing gonadal deletion of PPAR2. To determine the degree to which 
levels of mRNA for PPAR= were reduced in the gonads of PPAR=fl/fl;Amhr2cre/wt 
mice, PCR was used to amplify PPAR= from ovarian DNA.  Ovarian DNA was 
extracted as described above with the following modifications.  Ovarian tissue was 
dissolved in 400 Ul of extraction buffer (100 mM NaCl, 10 mM Tris-HCl pH 8.0, 25 
mM EDTA pH 8.0, 0.5% SDS, and 0.1 mg/ml proteinase K) and incubated at 55°C 
overnight with rotation.  DNA was extracted twice with phenol:chloroform:iso-amyl 
alcohol and precipitated with 40 Ul of 3 M sodium acetate and 1 ml of cold 100% 
ethyl alcohol.  DNA was resuspended in 10 Ul TE.  The resultant bands were 
quantified by densitometry (Alpha Imager, Innotech, San Leandro, CA). 
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Statistical analysis. Breeding parameters were tested for differences 
between crox mice homo- and heterozygous for flox insertions by Student’s t-test.  A 
p-value of p < 0.05 was considered significant. 
 
RESULTS 
To explore the function of PPAR= in the ovary, mice with PPAR= reduced 
specifically in ovarian tissue were generated (referred to as the crox line).  Mice 
homozygous for a pair of loxP insertions flanking exon 2 of PPAR= (referred to as the 
flox line) were crossed with mice that express Cre recombinase activity (referred to as 
the cre line).  All mice were genotyped for the presence of floxed PPAR= and Cre 
recombinase alleles in DNA collected from tail biopsies.   
Targeted deletion of PPAR= in the ovary was verified by extracting and 
amplifying whole ovary genomic DNA (Figure 4-2).  Mice carrying the floxed 
PPAR= allele and Cre recombinase gene produced a shortened, non-functional (or 
null) product of the PPAR= gene and a functional band of PPAR=. The degree to 
which PPAR= was reduced in the ovary was determined by comparing the amount of 
genomic ovarian DNA encoding the floxed allele for PPAR= to that encoding the 
PPAR= null-allele in PPAR=fl/fl;Amhr2cre/wt mice.  Crox mice expressing Cre 
recombinase produced the null PPAR= product, indicating that recombination had 
occurred, disrupting the expression of PPAR=. Large variance to the extent in which 
PPAR= was knocked-down was observed between individual mice of the same 
genotype (Figure 4-2). 
To assess the role of PPAR= on reproduction, various breeding parameters 
were recorded.  Mice with reduced expression of PPAR= (PPAR=fl/fl;Amhr2cre/wt), on 
average, gave birth to litters with fewer pups than did mice with intact expression of 
PPAR= (PPAR=fl/wt;Amhr2cre/wt; p < 0.05, Table 4-1). The length of time it took for 
females to conceive was determined by comparing the number of days between 
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joining the male and female and the day of parturition.  No differences were observed 
in the number of days per litter between homo- or heterozygous matings. 
 
DISCUSSION 
In the current study, mice expressing Cre recombinase inserted into the 
Amhr2 gene [19] were used to knock-down expression of PPAR= in the ovary.  
Amhr2 is expressed only in the granulosa cells, allowing Cre recombinase to only be 
expressed in granulosa cells [21; 22].  Therefore, Cre recombinase is inserted in the 
same cells expressing PPAR= (granulosa cells).  Mice with loxP insertions flanking 
PPAR= were previously generated to study the effects of PPAR= on cholesterol efflux 
[18].  Mating of these two previously inbred mouse lines produce a model to 
investigate the role of PPAR= in the ovary. 
Although several studies have focused on the function of PPAR= in the ovary, 
it is still unclear what role(s) this transcription factor plays in ovarian biology.  
Previous attempts to develop a viable, whole-genome PPAR= knock-out mouse have 
been unsuccessful [17].  Deficiency of PPAR= prevents normal placental 
vascularization resulting in embryonic lethal mutants [17].  Other methods, such as 
RNA interference (RNAi), have been successful in reducing PPAR= expression in 
vitro [23].  However, use of RNAi to lower PPAR= expression in vivo, a more 
appropriate method of investigating the effect of PPAR= on reproduction, has yet to 
be successful.  
The data presented here describe the characterization of F2 progeny generated 
by the crossing of mice containing both the floxed PPAR= allele and Cre recombinase 
gene.  To minimize the potential effects of hybrid vigor on fertility, crox mice 
(PPAR=fl/fl;Amhr2cre/wt) were back-crossed to the flox founder mouse line for six 
generations.  Future studies utilizing the crox line of mice will provide important 
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information regarding the expression of genes regulated by PPAR= in the ovary, and 
what effects it has on fertility.   
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Figure 4-1. Schematic diagram of the breeding program to establish mice with 
disrupted expression of PPAR= in the ovary, as described in the Methods and 
Materials.  Flox mice have loxP insertions flanking exon 2 of PPAR=
(PPAR=fl/fl;Amhr2wt/wt).  Cre identifies the founder line of mice with insertion of Cre 
recombinase into the gene encoding Amhr2 (PPAR=wt/wt;Amhr2cre/wt).  Crox 
represents the hybrid expressing Cre recombinase and carrying floxed alleles for 
PPAR= (PPAR=fl/fl;Amhr2cre/wt).
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Figure 4-2.  Amplification of PPAR= from genomic DNA extracted from ovarian 
tissue.  Tissues were collected and analyzed by PCR as described in the Materials and 
Methods.  Amplification of the floxed PPAR= allele (fl) produced a 275 bp DNA 
fragment (flox).  In the presence of Cre recombinase (Cre), the recombination of 
PPAR= yielded a 400 bp DNA fragment (null).    
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Genotype 
Animal 
ID 
Total 
Litters Pups/Litter 
Total 
Pups 
Days 
Mated Days/Litter 
=fl/wtAmhr2cre/wt X62 3.0 8.7 26.0 69.0 23.0 
X70 3.0 6.3 19.0 71.0 23.7 
 X71 3.0 7.7 23.0 75.0 25.0 
 X90 4.0 8.8 35.0 84.0 21.0 
 
Means 
± SEM 
3.3 ± 
0.2 7.9 ± 0.5** 
25.8 ± 
2.9 
74.8 ± 
2.9 23.2 ± 0.7 
=fl/flAmhr2cre/wt X60 2.0 5.0 10.0 38.0 19.0 
 X68 3.0 9.0 27.0 66.0 22.0 
 X69 4.0 9.5 38.0 128.0 32.0 
 X72 6.0 3.5 21.0 124.0 20.7 
 X78 5.0 6.2 31.0 113.0 22.6 
 X81 4.0 4.8 19.0 83.0 20.8 
 X85 3.0 6.0 18.0 86.0 28.7 
 
Means 
± SEM 
3.9 ± 
0.5 6.3 ± 0.8 
23.4 ± 
3.5 
91.1 ± 
12.4 23.7 ± 1.8 
Table 4-1. Breeding data collected from female crox mice.  Females expressing Cre 
recombinase and either hetero- or homozygous for loxP insertion into PPAR= (=fl/wt or 
=fl/fl), were mated with males of the following genotypes: PPAR=fl/fl;Amhr2cre/wt and 
PPAR=fl/wt;Amhr2wt/wt. Breeding data from individual females are presented above.  
Number of litters, number of pups, and total days mated were recorded.  Male mice 
remained with females throughout the recording period.  Days between litters (total 
days mated/total number of litters) is used as a measure of fertility by determining the 
time needed for conception, gestation, and parturition. ** indicates significant 
difference (p<0.05). 
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